

Tuberculosis profile: Bolivia (Plurinational State of)

Population 2020: 12 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	12 000 (8 000-17 000)	105 (68-149)
HIV-positive TB incidence	500 (320-720)	4.3 (2.7-6.2)
HIV-negative TB mortality	1 300 (940-1 800)	11 (8.1-15)
HIV-positive TB mortality	99 (71-130)	0.84 (0.6-1.1)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2020	49% (34-75)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	12% (7-18)

TB case notifications, 2020

Total new and relapse	6 007
- % tested with rapid diagnostics at time of diagnosis	100%
- % with known HIV status	87%
- % pulmonary	80%
- % bacteriologically confirmed ^	94%
- % children aged 0-14 years	4%
- % women (aged ≥15 years)	35%
- % men (aged ≥15 years)	61%
Total cases notified	6 105

TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	283	5.4%
- on antiretroviral therapy		

Drug-resistant TB care**, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	86%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	89%
Laboratory-confirmed cases - MDR/RR-TB ^^	99
Patients started on treatment - MDR/RR-TB ^^	83
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	1
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	1
MDR/RR-TB cases tested for resistance to any fluoroquinolone	29

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	83%	7 461
Previously treated cases, excluding relapse, registered in 2019	51%	134
HIV-positive TB cases registered in 2019		
MDR/RR-TB cases started on second-line treatment in 2018	70%	87
XDR-TB cases started on second-line treatment in 2018		0


TB preventive treatment, 2020

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	82% (76-91)


TB financing

National TB budget, 2021 (US\$ millions)	4
- Funding source, domestic	44%
- Funding source, international	56%
- unfunded	0%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2020 (Number)



Cases attributable to five risk factors, 2020 (Number)



Total budget (US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
 ** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
 ^ Calculated for pulmonary cases only
 ^^ Includes cases with unknown previous TB treatment history
 ^^ Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed